MedCity News

JUNE 18, 2024

The post Cancer Biotech Day One Biopharma Expands to ADCs, Paying $55M to Nab a Phase 1-Ready Drug appeared first on MedCity News. Day One Biopharmaceuticals is adding an antibody drug conjugate to its pipeline, licensing rights to a molecule from MabCare Therapeutics.

Biopharma 313

Biopharma Pharma 313

MedCity News

MARCH 28, 2025

The post Novo Nordisk Lands Lexicon Pharma Obesity Drug With Potential to Pair With GLP-1s appeared first on MedCity News. The licensing agreement comes months after Lexicon reported encouraging preclinical data from tests of LX9851 in combination with semaglutide, the main ingredient in Novo Nordisks Wegovy.

Pharma 170

Pharma Pharmaceutical Biopharma 170

MedCity News

NOVEMBER 25, 2024

BridgeBio Pharma claims its drug, Attruby, has an edge over a Pfizer drug as a treatment for cardiomyopathy caused by transthyretin-mediated amyloidosis. But new competition to both products could come soon from Alnylam Pharmaceuticals, now set to receive an FDA decision in this indication by late March.

Competition 300

Competition FDA Pharma Pharmaceutical 300

MedCity News

JANUARY 12, 2025

Gilead Sciences is acquiring LEO Pharmas oral small molecule inhibitors of STAT6, a protein key to two validated inflammation pathways. Other STAT6 drug developers include Kymera Therapeutics and Sanofi-partnered Recludix Pharma, which is presenting this week during the J.P. Morgan Healthcare Conference.

Pharma 260

Pharma Healthcare Healthcare Biopharma 260

Fierce Pharma

OCTOBER 30, 2024

Biopharma production efforts are set to receive a big boost in the U.K. thanks to a new budget rolled out by the Labour Party following this summer’s general election. | As part of the new budget presented Wednesday by the U.K.’s

Manufacturing 209

Manufacturing Biopharma Medical 209

MedCity News

MARCH 17, 2025

AstraZenecas EsoBiotec acquisition is the latest in a series of deals struck by the pharma giant to secure a place in the next wave of cell therapies for cancer and immune-mediated diseases. EsoBiotecs allogeneic cell therapies are made by the in vivo reprogramming of a patients immune cells.

Pharma 274

Pharma Patients Biopharma 274

Fierce Pharma

DECEMBER 19, 2024

In a move that follows an increasingly common trend in biopharma M&A, Novartis is shedding sites and staffers from the German cancer biotech it acquired earlier this year. Novartis confirmed Thursday that its closing down MorphoSys sites in Munich and Boston in a move thats expected to result in around 330 layoffs.

Biopharma 201

Biopharma 201

MedCity News

JANUARY 23, 2025

Astellas Pharma still looks to grow in cancer with a pipeline that includes internally developed programs that could stand out in oncology. But the drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer Tadaaki Taniguci said.

Pharma 273

Pharma Medical Biopharma 273

MedCity News

JANUARY 31, 2025

The post Vertex Pharmas Opioid Alternative Wins FDA Approval, First in a New Class of Pain Meds appeared first on MedCity News. Vertex Pharmaceuticals Jounavx is now FDA approved, providing patients a non-opioid option for treating acute pain.

FDA 270

FDA Medicine Pharma Pharmaceutical 270

MedCity News

MARCH 12, 2025

Roche will share in developing and commercializing petrelintide, a clinical-stage Zealand Pharma drug that activates the amylin receptor to spark weight loss. This agreement represents the highest total financial consideration in the obesity field to date.

Pharma 225

Pharma Biopharma 225

Fierce Pharma

AUGUST 27, 2024

An expert recently discussed the ramifications of the ruling during a Fierce Pharma podcast interview. . | In June, when the Supreme Court voted 6-3 to overturn the Chevron doctrine, it brought significant impact for the healthcare industry and federal regulators like the FDA and the Centers for Medicare & Medicaid Services.

Biopharma 280

Biopharma FDA Pharma Healthcare 280

MedCity News

NOVEMBER 4, 2024

This product candidate will be developed with Ascendis Pharma technology that has already yielded two FDA-approved products with longer dosing intervals. The Novo Nordisk/Ascendis partnership’s lead program is once-monthly injectable semaglutide for type 2 diabetes and obesity.

Pharma 300

Pharma FDA Leads Biopharma 300

Fierce Pharma

NOVEMBER 5, 2024

works to pump fresh cash into the local biopharma scene, London’s Accord Healthcare is capitalizing on the government’s renewed willingness to chip in. As the U.K. Flush with a 50 million pound sterling ($65 million) joint investment deal from the U.K.,

Biopharma 170

Biopharma Manufacturing Healthcare Healthcare 170

MedCity News

APRIL 14, 2024

The post A Wearable Tech Gives Pharmas & Therapists Better Feel for Changes in Mental Health appeared first on MedCity News. Pharmaceutical companies use Feel Therapeutics’ technology to monitor the mental state of participants in clinical trials of behavioral medications.

Pharma 331

Pharma Medical Pharmaceutical Biopharma 331

MedCity News

OCTOBER 21, 2024

The post Astellas Pharma Lands a First-in-Class Drug Approval in Rare Gastrointestinal Cancer appeared first on MedCity News. The FDA approved Astellas’s Vyloy as a treatment for advanced cases of gastric or gastroesophageal junction (GEJ) adenocarcinoma positive for a protein called claudin 18.2.

Pharma 326

Pharma FDA Biopharma 326

MedCity News

FEBRUARY 19, 2025

The post Recursion Pharma Accelerator Steps In to Fill Some of the Funding Gap Amid NIH Tumult appeared first on MedCity News. Altitude Lab Fund will provide pre-seed funding for early-stage startups affected by changes to grant programs administered by the National Institutes of Health.

Pharma 158

Pharma Pharmaceutical Biopharma 158

MedCity News

OCTOBER 14, 2024

Longboard Pharma Acquisition appeared first on MedCity News. Last month, the biotech began a Phase 3 clinical trial testing the drug in Dravet syndrome. The post Lundbeck’s Neuro-Rare Pipeline Lands Cornerstone Drug via $2.6B

Pharma 311

Pharma Pharmaceutical Biopharma 311

MedCity News

JULY 28, 2024

Sun Pharma added the oral drug to its pipeline via the $576 million acquisition of Concert Pharmaceuticals last year. The post FDA Approval of Alopecia Drug Positions Sun Pharma to Compete With Eli Lilly, Pfizer appeared first on MedCity News. Leqselvi is now FDA approved for treating severe alopecia areata.

FDA 284

FDA Pharma Pharmaceutical Biopharma 284

MedCity News

AUGUST 12, 2024

FDA approval of Ascendis Pharma’s Yorvipath is just in time for patients with hypoparathyroidism as Takeda Pharmaceutical will soon stop making the only drug therapy for the rare disorder. The post Ascendis Pharma Lands Long-Awaited FDA Drug Approval in Rare Hormone Deficiency appeared first on MedCity News.

FDA 301

FDA Pharma Competition Pharmaceutical 301

MedCity News

OCTOBER 20, 2024

The post How Generative AI Will Find a Place in the Pharma Industry Now and in the Years to Come appeared first on MedCity News. Pharmaceutical and biotech companies are using generative AI to predict drug-target interactions, optimize lead compounds, and generate novel molecular structures.

Pharma 329

Pharma Leads Pharmaceutical Biopharma 329

MedCity News

SEPTEMBER 16, 2024

The post New Eli Lilly Eczema Drug Brings Competition and Dosing Edge Versus Sanofi, LEO Pharma Meds appeared first on MedCity News. Eli Lilly drug Ebglyss is now FDA-approved for atopic dermatitis, an inflammatory skin disorder also known as eczema. The biologic drug came from Lilly’s $1.1 billion acquisition of Dermira in 2020.

Competition 313

Competition Pharma FDA Biopharma 313

MedCity News

JUNE 27, 2024

Verona Pharma’s COPD drug Ohtuvayre is a single small molecule that blocks two targets to bring patients both bronchodilation and anti-inflammatory effects. The post Verona Pharma Drug With Dual Mechanism Lands FDA Approval in COPD appeared first on MedCity News.

Pharma 284

Pharma FDA Medical Patients 284

MedCity News

MARCH 24, 2025

Separately, the pharma giant said its recently announced discounted price for obesity medication Wegovy is now expanding to traditional pharmacies. Novo Nordisk is licensing rights to a United Biotechnology drug that sparks metabolic effects by binding to and activating receptors for GLP-1, GIP, and glucagon.

Pharma 225

Pharma Medical Biopharma 225

MedCity News

OCTOBER 15, 2024

PurpleLab® stands out from others in this sector by providing its data analytics services to several different groups of users across healthcare and pharma companies. The post The Future of Hospitals and Pharma Companies Will Depend on Strength of Healthcare Analytics Insights appeared first on MedCity News.

Healthcare 291

Healthcare Healthcare Pharma Pharmaceutical 291

MedCity News

SEPTEMBER 24, 2024

The post Pain Meds, Cell Therapies & More: Vertex Pharma CEO Talks About What’s Next After Cystic Fibrosis appeared first on MedCity News. Vertex Pharmaceuticals is known for its cystic fibrosis drugs, but the company aims to diversify with a pipeline that reaches more therapeutic areas.

Pharma 301

Pharma Pharmaceutical Medical Biopharma 301

Fierce Pharma

MARCH 11, 2024

The decades-long wait for an effective treatment for metabolic dysfunction-associated steatohepatitis (MASH) has ended, as the FDA has approved the first drug for the fatty liver disease. | The decades-long wait for an effective treatment for metabolic dysfunction-associated steatohepatitis (MASH) has ended.

FDA 349

FDA Biopharma 349

MedCity News

DECEMBER 16, 2024

Separately, the pharma giant said all regulatory conditions have been met for Novo Holdings acquisition of Catalent, which will bring to Novo Nordisk three manufacturing sites for GLP-1 medications. Novo Nordisks new Denmark site will produce drugs for rare diseases, such as hemophilias.

Manufacturing 259

Manufacturing Pharma Medical Biopharma 259

Fierce Pharma

MAY 10, 2024

Right after an industry survey suggested that switching away from Chinese CDMOs could take biopharma companies up to eight years, lawmakers have adjusted the BIOSECURE Act. The new draft lays out a 2032 deadline for the separation mandate.

Biopharma 304

Biopharma 304

MedCity News

SEPTEMBER 9, 2024

The post Terns Pharma Oral GLP-1 Drug Leads to Greater Than 5% Weight Loss in Small Study appeared first on MedCity News. Terns is one of several companies developing oral GLP-1 obesity medications that could become alternatives to currently available injectable products from this drug class.

Leads 300

Leads Pharma Pharmaceutical Medical 300

MedCity News

JANUARY 24, 2025

Ascentage Pharmas U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced cases of certain blood cancers. Takeda holds an exclusive option to develop and commercialize one of those drugs in most of the world. The post Ascentage Has First U.S.

Pharma 225

Pharma Leads Biopharma 225

pharmaphorum

NOVEMBER 12, 2024

AstraZeneca plans to invest a whopping $3.5

Biopharma 98

Biopharma Sales Manufacturing Pharma 98

Fierce Pharma

DECEMBER 2, 2024

Department of Health and Human Services immediately sent waves of speculation swirling throughout the biopharma industry. | Kennedy Jr.’s s appointment last month to lead the U.S. The former FDA Commissioner pointed to the threat of measles if vaccination rates were to decline by 5%.

Biopharma 67

Biopharma FDA Leads 67

Fierce Pharma

AUGUST 20, 2024

As House lawmakers prepare for a September vote on the controversial BIOSECURE Act, the House Select Committee on the CCP is expanding the scope of its scrutiny on China's biopharma ecosystem. |

Biopharma 289

Biopharma FDA 289

MedCity News

MARCH 25, 2024

AbbVie is acquiring Landos Biopharma, whose lead drug is a small molecule that takes a novel approach to treating ulcerative colitis. Preliminary proof-of-concept data from a Phase 2 study are expected later this year.

Biopharma 313

Biopharma Leads Pharma 313

MedCity News

MARCH 25, 2025

Apellis Pharmaceuticals and Astellas Pharma have the first two FDA-approved therapies for geographic atrophy, but Character Biosciences claims its approach could be best in class for treating this advanced form of dry age-related macular degeneration.

Pharma 170

Pharma FDA Pharmaceutical Biopharma 170

Fierce Pharma

NOVEMBER 6, 2024

As other biopharma giants have divested their generics units to focus on the development and commercialization of innovative drugs, Teva has relied on its copycat business to help trigger its rebou | Teva revealed booming third-quarter sales for its generics and biosimilars. In the U.S., revenue from the knockoffs came in at $1.1

Biopharma 132

Biopharma Sales 132

Fierce Pharma

DECEMBER 14, 2023

Pfizer’s $43 billion acquisition of Seagen is in the books, as it becomes the largest M&A transaction in the biopharma industry since AbbVie snatched up Allergan for $63 billion in 2019. Pfizer’s $43 billion acquisition of Seagen is in the books, the company said on Thursda | It’s a done deal.

Biopharma 353

Biopharma 353